Comparative efficacy of indacaterol in chronic obstructive pulmonary disease Full Text
International Journal of COPD,  Clinical Article

Ribeiro M et al. – Data from trials with the novel once–daily β2–agonist, indacaterol, indicate superior bronchodilation and clinical efficacy over twice–daily long–acting β2–agonists and at least equipotent bronchodilation as once–daily tiotropium. Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). It is likely that once–daily dosing of a bronchodilator would be a significant convenience and probably a compliance–enhancing advantage, leading to improved overall clinical outcomes in patients with COPD.

  • Long–acting bronchodilators have been shown to improve multiple clinical outcomes in chronic obstructive pulmonary disease (COPD) including lung function, symptoms, dyspnea, quality of life, and exacerbations.
  • Indacaterol is a novel, inhaled, long–acting β2–agonist providing 24–hour bronchodilation with once–daily dosing.
  • It is currently approved for the maintenance treatment of COPD to be administered as 150 or 300 µg once–daily doses as licensed in many countries and 75 µg as licensed in the US by means of a single–dose dry powder inhaler.
  • The data from clinical development support a favorable safety and tolerability profile within the β2–agonist drug class, with no relevant issues identified.
  • Current evidence indicates that indacaterol is suitable for use as first–line monotherapy in COPD patients with moderate disease (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) and beyond that do not require an inhaled corticosteroid (ICS) as per GOLD guidelines, or in combination with an ICS in severe or very severe patients with repeated exacerbations.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Pulmonology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Pulmonology Articles

Indexed Journals in Pulmonology: Chest, Thorax, American Journal of Respiratory and Critical Care Medicinemore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List